<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1602256904
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XALATAN 50MCG\ML EYE DROP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LATANOPROST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        42.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Upjohn SRL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01EE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Xalatan belongs to a group of medicines known as prostaglandin analogues. It works by increasing the natural outflow of fluid from inside the eye into the bloodstream.</p><p>&nbsp;</p><p>Xalatan is used to treat conditions known as <strong>open angle glaucoma</strong> and <strong>ocular hypertension</strong> in adults. Both of these conditions are linked with an increase in the pressure within your eye, eventually affecting your eye sight.</p><p>&nbsp;</p><p>Xalatan is also used to treat increased eye pressure and glaucoma in all ages of children and babies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xalatan can be used in adult men and women (including the elderly) and in children from birth to 18 years of age. Xalatan has not been investigated in prematurely born infants (less than 36 weeks gestation).</p><p>&nbsp;</p><p>Do not use Xalatan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to latanoprost or any of the other ingredients of Xalatan (listed in section 6)</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor or the doctor treating your child or pharmacist before using Xalatan or before you give this to your child if you think any of the following apply to you or your child:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your child are about to have or have had eye surgery (including cataract surgery)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your child suffer from eye problems (such as eye pain, irritation or inflammation, blurred vision)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your child suffers from dry eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your child have severe asthma or the asthma is not well controlled</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or your child wear contact lenses. &nbsp;You can still use Xalatan, but follow the instruction for contact lens wearers in Section 3</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered or are currently suffering from a viral infection of the eye caused by the herpes simplex virus (HSV)</p><p><strong>&nbsp;</strong></p><p>Other medicines and Xalatan</p><p>Xalatan may interact with other medicines.&nbsp; Please tell your doctor, the doctor treating your child or pharmacist if you or your child are using or have used any other medicines including those medicines (or eye drops) obtained without a prescription. In particular, speak to your doctor or pharmacist if you know that you are taking prostaglandins, prostaglandin analogues or prostaglandin derivatives.</p><p>&nbsp;</p><p>Pregnancy and breast feeding</p><p>You should not use Xalatan if you are pregnant or breast-feeding, unless your doctor considers it necessary. If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>When you use Xalatan you might have blurred vision, for a short time. If this happens to you, <strong>do not drive</strong> or use any tools or machines until your vision becomes clear again.</p><p>&nbsp;</p><p>Xalatan contains Benzalkonium chloride and phosphate buffers</p><p>This medicine contains 0.2 mg/mL of benzalkonium chloride.</p><p>&nbsp;</p><p>Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards.</p><p>&nbsp;</p><p>Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.</p><p>&nbsp;</p><p>This medicine contains 6.3 mg/mL phosphates which is equivalent to 0.2 mg/drop.</p><p>&nbsp;</p><p>If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Xalatan exactly as your doctor or the doctor treating your child has told you. You should check with your doctor or the doctor treating your child or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dosage for adults (including the elderly) and children is one drop once a day in the affected eye(s). The best time to do this is in the evening.</p><p>&nbsp;</p><p>Do not use Xalatan more than once a day, because the effectiveness of the treatment can be reduced if you administer it more often.</p><p>&nbsp;</p><p>Use Xalatan as instructed by your doctor or by the doctor treating your child until they tell you to stop.</p><p>&nbsp;</p><p><strong>Contact lens wearers</strong></p><p>If you or your child wear contact lenses, they should be removed before using Xalatan. After using Xalatan you should wait 15 minutes before putting the contact lenses back into the eyes.</p><p>&nbsp;</p><p>Instructions for use</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands and sit or stand comfortably.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist off the outer cap (which can be thrown away).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unscrew the protective inner cap.&nbsp; The protective cap should be retained.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use your finger to gently pull down the lower eyelid of your affected eye.</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the tip of the bottle close to, but not touching your eye.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Squeeze the bottle gently so that only one drop goes into your eye, then release the lower eyelid.</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press a finger against the corner of the affected eye by the nose. Hold for 1 minute whilst keeping the eye closed.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat in your other eye if your doctor has told you to do this.</p><p>&nbsp;</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the protective inner cap back on the bottle.</p></td></tr></tbody></table><p>&nbsp;</p><p>If you use Xalatan with other eye drops</p><p>Wait at least 5 minutes between using Xalatan and taking other eye drops.</p><p>&nbsp;</p><p>If you use more Xalatan than you should</p><p>If you put too many drops into the eye, it may lead to some minor irritation in the eye and the eyes may water and turn red. This should pass, but if you are worried contact your doctor or the doctor treating your child for advice.</p><p>&nbsp;</p><p>Contact your doctor as soon as possible if you or your child swallows Xalatan accidentally.</p><p>&nbsp;</p><p>If you forget to use Xalatan</p><p>Carry on with the usual dosage at the usual time. Do not take a double dose to make up for the dose you have forgotten. If you are unsure about anything talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>If you stop using Xalatan</p><p>You should speak to your doctor or the doctor treating your child if you want to stop taking Xalatan.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following are known side effects of using Xalatan:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A gradual change in your eye colour by increasing the amount of brown pigment in the coloured part of the eye known as the iris. If you have mixed-colour eyes (blue-brown, grey-brown, yellow-brown or green-brown) you are more likely to see this change than if you have eyes of one colour (blue, grey, green or brown eyes). Any changes in your eye colour may take years to develop although it is normally seen within 8 months of treatment. The colour change may be permanent and may be more noticeable if you use Xalatan in only one eye. There appears to be no problems associated with the change in eye colour. The eye colour change does not continue after Xalatan treatment is stopped.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the eye.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye irritation (a feeling of burning, grittiness, itching, stinging or the sensation of a foreign body in the eye). If you experience eye irritation severe enough to make your eyes water excessively, or make you consider stopping this medicine, talk to your doctor, pharmacist or nurse promptly (within a week). You may need your treatment to be reviewed to ensure you keep receiving appropriate treatment for your condition.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A gradual change to eyelashes of the treated eye and the fine hairs around the treated eye, seen mostly in people of Japanese origin. These changes involve an increase of the colour (darkening), length, thickness and number of your eye lashes.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritation or disruption to the surface of the eye, eyelid inflammation (blepharitis), eye pain, light sensitivity (photophobia), conjunctivitis.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eyelid swelling, dryness of the eye, inflammation or irritation of the surface of the eye (keratitis), blurred vision, inflammation of the coloured part of the eye (uveitis), swelling of the retina (macular oedema).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain (angina), awareness of heart rhythm (palpitations).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma, shortness of breath (dyspnoea).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain, joint pain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting.</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the iris (iritis), symptoms of swelling or scratching/damage to the surface of the eye, swelling around the eye (periorbital oedema), misdirected eyelashes or an extra row of eyelashes, scarring of the surface of the eye, fluid filled area within the coloured part of the eye (iris cyst).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions on the eyelids, darkening of the skin of the eyelids.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of asthma.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe itching of the skin.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developing a viral infection of the eye caused by the herpes simplex virus (HSV).</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of angina in patients who also have heart disease, sunken eye appearance (eye sulcus deepening).</p><p>&nbsp;</p><p>Side effects seen more often in children compared to adults are runny itchy nose and fever.</p><p>&nbsp;</p><p>In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store the unopened bottle in a refrigerator (2&deg;C &ndash; 8&deg;C)</p><p>&nbsp;</p><p>After opening the bottle, do not store above 25&deg;C and use within 4 weeks of opening. When you are not using Xalatan, keep the bottle in the outer carton, in order to protect it from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a- What Xalatan contains</p><p>&nbsp;</p><p>The active substance is 50&nbsp;micrograms/mL latanoprost.</p><p>The other ingredients are: benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate monohydrate and disodium phosphate anhydrous dissolved in water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xalatan Eye drops is a clear, colourless liquid.
Xalatan is available in pack sizes of 1, 3 or 6 bottles. Not all pack sizes may be marketed.
Each bottle contains 2.5 mL of Xalatan Eye drops.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Upjohn SRL, Boulevard De la Plaine 17, 1050 Bruxelles, Belgium.</p><p><strong>Manufacturer:</strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي زالاتان إلى مجموعة من الأدوية تُعرف باسم مضاهئات البروستاجلاندين. ويعمل من خلال زيادة التدفق الطبيعي للسوائل من داخل العين إلى مجرى الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم زالاتان لعلاج الحالات المرضية المعروفة باسم <strong>الزرق مفتوح الزاوية</strong> و<strong>ارتفاع ضغط العين</strong> في البالغين. ترتبط هاتان الحالتان بارتفاع الضغط في العين، مما يؤثر في النهاية على بصرك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم زالاتان أيضًا في علاج ارتفاع ضغط العين والزرق عند الأطفال والرضع بمختلف الأعمار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يُستخدم زالاتان لعلاج البالغين من الرجال والسيدات (بما في ذلك المسنون) والأطفال منذ الولادة وحتى عمر ١٨ عامًا. لم يتم اختبار زالاتان في الأطفال المبتسرين (فترة حمل أقل من ٣٦ أسبوعًا).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال زالاتان</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ ﺣﺴﺎﺳﯿﺔ (مصاب بفرط الحساسية) ﺗﺠﺎه لاتانوبروست أو أي من الﻣﻜﻮﻧﺎت الأﺧﺮى لزالاتان (اﻟﻤﺪرﺟﺔ ﻓﻲ اﻟﻘﺴم ٦)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زالاتان</strong></p><p dir="RTL">تحدث إلى طبيبك أو الطبيب المعالج لطفلك أو الصيدلي قبل استخدام زالاتان أو قبل إعطائه لطفلك إذا كنت تعتقد أن أيًا من الحالات التالية تنطبق عليك أو على طفلك:&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت<!--[if gte mso 11]><w:PermStart
 w:id="1144652778" w:edGrp="everyone"/><![endif]--><!--[if gte mso 11]><w:PermEnd
 w:id="1144652778"/><![endif]--> أو طفلك على وشك الخضوع أو خضعت لجراحة في العين (بما في ذلك جراحة إزالة إعتام عدسة العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو طفلك من مشكلات في العين (مثل ألم العين، تهيج العين أو التهابها، تغيم الرؤية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو طفلك من جفاف العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو طفلك من الربو الشديد أو إذا كنت لا تسيطر على حالة الربو بشكل جيد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تضع أنت أو طفلك عدسات لاصقة. يظل بمقدروك استخدام زالاتان، ولكن اتبع التعليمات الموجهة للذين يضعون العدسات اللاصقة في قسم ٣</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت من قبل أو كنت تعاني حاليًا من عدوى فيروسية في العين سبّبها فيروس الهربس البسيط (HSV)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يمكن أن يتفاعل زالاتان مع الأدوية الأخرى. يرجى إخبار طبيبك أو الطبيب المعالج لطفلك أو الصيدلي إذا كان أي منكما - أنت أو طفلك&nbsp; يستخدم أو قد استخدم من قبل أي أدوية أخرى بما في ذلك تلك الأدوية (أو قطرات العين) التي يمكن الحصول عليها دون وصفة طبية. بالأخص، تحدث إلى طبيبك أو الصيدلي إذا كنت تعلم أنك تتناول بروستاجلاندين، أو مشابهات بروستاجلاندين، أو مشتقات بروستاجلاندين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا ﻛﻧتِ ﺣﺎﻣ ًﻼ أو ﺗرﺿﻌﯾن رﺿﺎﻋﺔ طﺑﯾﻌﯾﺔ أو ﺗﻌﺗﻘدﯾن أﻧك رﺑﻣﺎ ﺗﻛوﻧﯾن ﺣﺎﻣ ًﻼ أو ﺗﺧططﯾن ﻟﻠﺣﻣل ﻓﺎﺳﺗﺷﯾري اﻟطﺑﯾب أو اﻟﺻﯾدﻟﻲ ﻗﺑل اﺳﺗﺧدام ھذا اﻟدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زالاتان على القيادة واستخدام الآلات</strong></p><p dir="RTL">عند استخدامك زالاتان قد تُصاب بتغيُّم الرؤية لمدة قصيرة من الوقت. إذا حدث لك هذا، <strong>فلا تقم بالقيادة</strong> أو استخدام أي أدوات أو آلات حتى تعود رؤيتك واضحة مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات زالاتان</strong></p><p dir="RTL"><strong>يحتوي زالاتان على كلوريد البنزالكونيوم وعوامل تثبيت الفوسفات</strong></p><p dir="RTL">يحتوي هذا الدواء على ٠.٢ ملجم/مل من كلوريد البنزالكونيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُمتصّ كلوريد البنزالكونيوم من قِبل العدسات اللاصقة اللينة وقد يغير لون العدسات اللاصقة. ينبغي نزع العدسات اللاصقة قبل استخدام هذا الدواء ثم قم بوضعها مرة أخرى بعد ١٥ دقيقة.</p><p dir="RTL"><br />قد يتسبب كلوريد البنزالكونيوم أيضًا في تهيج العين، وخاصةً إذا كنت تعاني من جفاف العين أو اضطرابات في القرنية (الطبقة الشفافة في مقدمة العين). إذا كان هناك شعور غير طبيعي في العين أو وخز أو ألم في العين بعد استخدام هذا الدواء، فتحدث إلى طبيبك.<br />&nbsp;</p><p dir="RTL">هذا الدواء يحتوي على ٦.٣ ملجم/مل من الفوسفات وهو ما يعادل ٠.٢ ملجم/قطرة.</p><p dir="RTL"><br />إذا كنت تعاني من تلف شديد في الطبقة الشفافة في مقدمة العين (القرنية)، فقد يتسبب الفوسفات في وجود بقع غائمة على القرنية في حالات نادرة للغاية نتيجة لتراكم الكالسيوم أثناء العلاج.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;ﺧذ ھذا اﻟدواء داﺋﻣﺎ وﻓﻘًﺎ ﻟوﺻﻔﺔ اﻟطﺑﯾب ﺗﻣﺎﻣًﺎ. ينبغي لك اﻟﺗﺣﻘقّ ﻣن اﻟطﺑﯾب أو ﻣن اﻟﺻﯾدﻟﻲ إذا ﻟم ﺗﻛن ﻣﺗﺄﻛّدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها بالنسبة للبالغين (بما في ذلك المسنون) والأطفال هي نقطة واحدة مرة يوميًا في العين (العينين) المصابة. أفضل وقت للقيام بذلك هو في المساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم زالاتان أكثر من مرة في اليوم، حيث أنه من الممكن أن تنخفض فعالية العلاج إذا استخدمته بشكل متكرر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم باستخدام زالاتان وفقًا لتعليمات طبيبك أو الطبيب المعالج لطفلك حتى يخبرك بإيقاف استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مستخدمو العدسات اللاصقة</strong></p><p dir="RTL">إذا كان طفلك يضع عدسات لاصقة، ينبغي نزعها قبل استخدام زالاتان. بعد استخدام زالاتان، ينبغي عليك الانتظار لمدة ١٥ دقيقة قبل وضع العدسات اللاصقة مرة أخرى في العينين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعليمات الاستخدام</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">١. اغسل يديك واجلس أو قف في وضع مريح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٢. قم بلف الغطاء الخارجي إلى الخارج )الذي يمكن التخلص منه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">٣. قم بفك الغطاء الواقي الداخلي. ينبغي الاحتفاظ بالغطاء الواقي.<br />&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">٤. استخدم إصبعك لشد الجفن السفلي لعينك المصابة برفق لأسفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٥. ضع الزجاجة بحيث تكون قريبة من عينك دون أن تلمسها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٦. اضغط على الزجاجة برفق حتى تدخل نقطة واحدة فقط لا أكثر في عينك، ثم اترك الجفن السفلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٧. اضغط بإصبعك على ركن العين المصابة المجاور للأنف. استمر بالضغط لمدة دقيقة واحدة بينما تبقي عينك مغمضة.</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">٨. كرر الأمر في عينك الأخرى إذا كان طبيبك قد وجهك إلى فعل هذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٩. ضع الغطاء الداخلي الواقي على الزجاجة مرة أخرى.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تستخدم زالاتان مع أنواع أخرى من قطرات العين</strong></p><p dir="RTL">فانتظر لمدة خمس دقائق على الأقل بين استخدام زالاتان وقطرات العين الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زالاتان</strong></p><p dir="RTL">إذا قمت بوضع قطرات عديدة من زالاتان في العين، فمن الممكن أن يؤدي هذا إلى حدوث تهيج طفيف في العين ويمكن للعينين أن تدمعا ويتحول لونهما إلى الأحمر. ينبغي أن تزول تلك الأعراض، ولكن إن أصبت بالقلق فاتصل بطبيبك أو الطبيب المُعالج لطفلك للمشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ابتلعت أنت أو طفلك زالاتان بالخطأ، فاتصل بطبيبك بأسرع ما يمكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زالاتان</strong></p><p dir="RTL">فاستمر باستخدام الجرعة المعتادة في الوقت المعتاد. ولا تضع جرعة مضاعفة لتعويض الجرعة التي قد نسيتها. إذا كنت غير متأكد بشأن أي شيء، فتحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول زالاتان</strong></p><p dir="RTL">إذا كنت ترغب في التوقف عن استخدام زالاتان، ينبغي عليك استشارة طبيبك أو الطبيب المعالج لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، إلّا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الآثار الجانبية المعروفة لاستخدام زالاتان:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُر تدريجي في لون العين عن طريق زيادة نسبة الصبغة البنية في الجزء الملون من العين الذي يُسمى القزحية. إذا كانت عينيك مختلطة اللون (بني مائل للزرقة، أو بني مائل للرمادي، أو بني مائل للصفرة، أو بني مائل للخضرة) فقد تزيد احتمالات حدوث هذه التغييرات عما إذا كان لون عينيك واحدًا (عيون زرقاء أو رمادية أو خضراء أو بنية). قد تأخذ أي تغيرات في لون العين أعوامًا حتى تظهر على الرغم من أنها تظهر عادةً خلال ٨ أشهر من العلاج. يمكن لتغير اللون أن يكون دائمًا وقد يُلاحَظ بشكل أكبر إذا كنت تستخدم زالاتان في عين واحدة فقط. لم تتم ملاحظة حدوث مشاكل مرتبطة بتغير لون العين. لا يستمر التغير في لون العين بعد إيقاف العلاج بزالاتان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العين (شعور بحرقان أو إحساس يشبه لوجود رمال في العين، أو حكة، أو شعور بالوخز، أو شعور بوجود جسم غريب في العين). إذا أصبت بتهيج بالعين شديد الحدة بقدرٍ كافٍ لتدمع عينيك بشكل زائد أو ليجعلك تفكر في التوقف عن استخدام هذه الدواء، فتحدث إلى طبيبك أو الصيدلي أو الممرضة على الفور (خلال أسبوع). قد تكون بحاجة إلى أن تتم مراجعة علاجك للتأكد من استمرارك في تلقي العلاج المناسب لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات تدريجية في أهداب العين التي تتم معالجتها والشعر الرقيق المحيط بها، يلاحظ حدوثها غالبًا في الأشخاص من أصل ياباني. تتضمن هذه التغيرات زيادة في لون أهداب العين (يصبح داكنًا) وطولها وكثافتها وعددها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج أو اضطراب سطح العين، التهاب الجفنين، ألم العين، الحساسية للضوء (فوبيا الضوء)، التهاب الملتحمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفنين، جفاف العين، التهاب أو تهيج سطح العين (التهاب القرنية)، تغيم الرؤية، التهاب الجزء الملون من العين (التهاب العنبية)، تورم الشبكية (التورم البقعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر (الذبحة الصدرية)، الإحساس بنبضات القلب (الخفقان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو، ضيق التنفس (عسر التنفس).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، الدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات، ألم المفاصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب ما يصل إلى شخص واحد من ١٠٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القزحية، أعراض تورم أو حدوث خدش/تلف في سطح العين، تورم حول العين (تورم الجزء المحيط بجسم العين (الحجاج))، نمو الأهداب في اتجاه غير صحيح أو نمو صف زائد من الأهداب، تندُّب سطح العين، منطقة مملوءة بالسائل داخل الجزء الملون من العين (كيسة القزحية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية بالجفنين؛ اسمرار جلد الجفنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالة الربو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بعدوى فيروسية في العين تسبب بها فيروس الهربس البسيط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تصيب ما يصل إلى شخص واحد من كل ١٠٠٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالة الذبحة الصدرية في المرضى الذين يعانون أيضًا من مرض قلبي، مظهر غائر للعينين (زيادة في عمق تَّلَم العين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية التي تمت ملاحظتها بشكل أكثر في الأطفال مقارنة بالبالغين هي سيلان في الأنف مصحوب بحكة وحمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة جدًا، ظهر لدى بعض المرضى المصابين بتلف شديد بالطبقة الشفافة في مقدمة العين (القرنية) بقع غيمية بالقرنية بسبب تراكم الكالسيوم أثناء العلاج.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية</strong></p><p dir="RTL">ﻓﻲ ﺣﺎل زادت اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ ﺳوءًا، أو ﻻﺣظت أﻋراضًا ﺟﺎﻧﺑﯾﺔ ﻏﯾر ﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة، ﻗم ﺑﺎﻟﺗواﺻل ﻣﻊ اﻟطﺑﯾب أو اﻟﺻﯾدﻟﻲ. إذا أُصبت بأي أعراض جانبية فتحدث إلى طبيبك، أو الصيدلي، أو الممرضة. وهذا يتضمن أي أعراض جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال الموحد: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: <em>npc.drug@sfda.gov.sa</em></li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em><em>- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العلبة الكرتونية والزجاجة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">قم بتخزين الزجاجة غير المفتوحة في المبرد (في درجة حرارة بين درجتين مئويتين و٨ درجات مئوية)، بحيث تكون محمية من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس من الضروري أن تخزن الزجاجة في المبرد بعد فتحها، ولكن يجب عليك عدم تخزينها في درجة حرارة أعلى من ٢٥ درجة مئوية. استخدمها خلال ٤ أسابيع من الفتح. في الأوقات التي لا تستخدم فيها زالاتان، احفظ الزجاجة في العلبة الكرتونية الخارجية من أجل حمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة اليها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ماهي محتويات زالاتان</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إن المادة الفعالة هي ٥٠ ميكروجرام/مل من لاتانوبروست.</p><p dir="RTL">المكونات الأخرى هي: كلوريد البنزالكونيوم، وكلوريد الصوديوم، وفوسفات الصوديوم ثنائي الهيدروجين أحادي الهيدرات، وفوسفات ثنائي الصوديوم اللامائي مذاب في ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قطرات زالاتان للعين هو سائل صافٍ عديم اللون.</p><p dir="RTL">يتوفر زالاتان في عبوات بأحجام ١، أو ٣، أو ٦ زجاجات. قد لا تُطرح جميع أحجام العبوات في الأسواق.</p><p dir="RTL">تحتوي كل زجاجة على ٢.٥ مل من قطرات زالاتان للعين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق:</strong></p><p dir="RTL">أبجون اس ار ال، بوليفارد لا بلين ١٧ ، ١٠٥٠ بروكسيل، بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p dir="RTL">مصنع فايزر ان في، رايكسفيج ١٢ ، ٢٨٧٠ بورس، بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌أ.       تمت الموافقة على هذه النشرة بتاريخ مارس/آذار ٢٠٢٢
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xalatan 50 micrograms/ml Eye drops, solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml Eye drops, solution contains 50 micrograms of latanoprost.
1 drop contains approximately 1.5 micrograms of latanoprost.

Excipient(s) with known effect
Benzalkonium chloride 0.2 mg/mL is included as a preservative.
Sodium dihydrogen phosphate monohydrate 4.60 mg/ml.
Disodium phosphate anhydrous 4.74 mg/ml.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.

The solution is a clear, colourless liquid.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduction of elevated intraocular pressure (IOP) in patients suffering from open-angle glaucoma and ocular hypertension in adults (including elderly subjects).</p><p>&nbsp;</p><p>Reduction of elevated IOP in paediatric patients with elevated IOP and paediatric glaucoma.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>&nbsp;</em></p><p><em>Adults (including elderly subjects)</em></p><p>The recommended dose is one drop per day in the affected eye(s). For an optimal effect, administer Xalatan in the evening.</p><p>&nbsp;</p><p>Xalatan may not be administered more than once per day, because it has been shown that more frequent administration decreases the IOP lowering effect.</p><p>&nbsp;</p><p>If a dose is missed, treatment should continue by administering the next dose at the regular time.</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>Xalatan Eye drops, solution may be used in children at the same posology as in adults. No data are available for preterm infants (gestational age less than 36 weeks). Data in the age group &lt; 1 year (4 patients) are very limited (see section 5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>As with all eye drops, to avoid possible systemic absorption, pressing on the lacrimal sac for one minute at the internal canthus (lachrymal point occlusion) is recommended immediately after administering each drop.</p><p>&nbsp;</p><p>Contact lenses should be removed before instillation of the eye drops and can be reinserted after 15 minutes.</p><p>&nbsp;</p><p>In case of ocular administration of multiple medicinal products, different medicinal products should be administered at an interval of at least 5 minutes.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Known hypersensitivity to latanoprost or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xalatan may progressively modify eye colour by increasing the quantity of brown pigment in the iris. Before starting treatment, patients should be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia.</p><p>&nbsp;</p><p>This change in eye colour has especially been observed in patients whose irises were multi-coloured, that is, blue-brown, grey-brown, yellow-brown or green-brown. In studies performed with latanoprost, this change generally appeared during the first 8 months of treatment, rarely during the second or third year, and was not observed after the fourth year of treatment. The rate of progression of iris pigmentation decreases over time and is stable after five years. The effect of increased pigmentation beyond five years has not been evaluated. In a 5-year, open-label safety study with latanoprost, 33% of patients developed iris pigmentation (see section 4.8).&nbsp; In most cases, the change in iris colour is mild; it is often not perceived clinically. Its incidence, in patients whose irises were multi-coloured, ranged from 7 to 85%; it was highest in patients whose irises were yellow-brown.&nbsp; In patients with uniformly blue eyes, no change was observed; in patients with uniformly grey, green or brown eyes, it was observed very rarely.</p><p>&nbsp;</p><p>The change in colour is due to an increase in melanin content in the stromal melanocytes of the iris, and not to an increase in number of melanocytes. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the affected eye, but it is possible that the entire iris or only parts may become browner. After stopping treatment, no subsequent increase in brown pigmentation has been observed. In clinical studies to date, this change has not been associated with any symptoms or pathological changes.</p><p>&nbsp;</p><p>Naevi and freckles of the iris are not affected by the treatment. No accumulation of pigment was observed in the trabecular meshwork or any other point in the anterior chamber during clinical studies. Based on clinical experience gathered over 5 years, the increase in iris pigmentation does not seem to have negative clinical consequences; administration of Xalatan may be continued in case of iris pigmentation. However, patients should be regularly monitored and, if the clinical situation so justifies, Xalatan treatment may be discontinued.</p><p>&nbsp;</p><p>Experience available about the use of Xalatan in chronic closed-angle glaucoma, in open-angle glaucoma in patients with artificial lenses and in pigmentary glaucoma is limited. There is no experience regarding use of Xalatan in inflammatory and neovascular glaucoma or in ocular inflammatory diseases. Xalatan has little effect, if any, on the pupil but there is no experience with acute closed-angle glaucoma attacks. It is therefore recommended that Xalatan should be used with caution in these conditions until more experience is available.</p><p>&nbsp;</p><p>Data regarding use of Xalatan in the perioperative period in cataract surgery are limited. In these patients, Xalatan should be used with caution.</p><p>&nbsp;</p><p>Xalatan should be used with caution in patients with a history of herpetic keratitis and should be avoided in the case of active herpes simplex keratitis, and in patients with recurrent herpetic keratitis specifically associated with prostaglandin analogues.</p><p>&nbsp;</p><p>Cases of macular oedema have been described (see section 4.8), mainly in aphakic patients, in pseudophakic patients with a torn posterior lens capsule or implanted anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema (such as diabetic retinopathy and retinal vein occlusion). Xalatan should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule or bearers of anterior chamber lenses, as well as in patients with known risk factors for cystoid macular oedema.</p><p>&nbsp;</p><p>Xalatan should be used with caution in patients with known risk factors for iritis/uveitis.</p><p>&nbsp;</p><p>Experience with Xalatan in asthmatic patients is limited, but some cases of worsening of the asthma and/or dyspnoea have been reported after post-marketing of Xalatan. Asthmatic patients should therefore be treated with necessary caution until there is sufficient experience; see section 4.8.</p><p>&nbsp;</p><p>Periorbital skin discolouration has been observed; the majority of cases were described in Japanese patients. Experience available at present shows that this change is not permanent and, in some cases, disappeared during continued treatment with Xalatan.</p><p>&nbsp;</p><p>Latanoprost may gradually change eyelashes and hair on the eyelid of the treated eye and surrounding areas; these changes include increased length, thickness, pigmentation, number of eyelashes or hairs and poorly directed growth of the eyelashes. Changes in the eyelashes are reversible when treatment stops.</p><p>&nbsp;</p><p><u>Preservative</u></p><p>Xalatan contains benzalkonium chloride, which is generally used as a preservative agent in ophthalmic products. From the limited data available, there is no difference in the adverse event profile in children compared to adults. Generally, however, eyes in children show a stronger reaction for a given stimulus than the adult eye. Irritation may have an effect on treatment adherence in children. Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface.. Xalatan should be used with caution in patients with ocular dryness or in patients in whom the cornea may be compromised. Patients should be monitored in case of prolonged use.</p><p>&nbsp;</p><p><u>Contact lenses</u></p><p>Contact lenses may absorb benzalkonium chloride; they should be removed before applying Xalatan but may be reinserted after 15 minutes (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Safety and efficacy data in the age group &lt; 1 year (4 patients) are very limited (see section 5.1). No data are available for preterm infants (gestational age less than 36 weeks).</p><p>&nbsp;</p><p>In children from 0 to &lt; 3 years old suffering from primary congenital glaucoma (PCG), surgery (i.e. trabeculotomy/goniotomy) remains the first line treatment.</p><p>&nbsp;</p><p>Safety of long-term use in children has not yet been established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No definitive drug-induced interaction data are available.</p><p>&nbsp;</p><p>Cases of paradoxical increases in IOP have been reported after concomitant ophthalmic administration of two prostaglandin analogues. The use of two or more prostaglandins, prostaglandin analogues or prostaglandin derivatives is not recommended.</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>Interaction studies have only been conducted in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>The safety of this medicinal product for use during pregnancy in humans has not been established. It may have toxic pharmacological effects on the course of pregnancy, on the unborn child or the newborn. Therefore, Xalatan should not be used during pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>Latanoprost and its metabolites can pass into breast milk. Therefore, Xalatan should not be used in breast-feeding women or breast-feeding should be stopped, if applicable.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No effect of latanoprost on male or female fertility has been observed in studies in animals (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xalatan has minor influence on the ability to drive and use machines. In common with other preparations for ophthalmic use, administration of eye drops may temporarily blur vision. Patients should not drive or use machines until their vision returns to normal.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a. Summary of the safety profile</u></p><p>The majority of adverse reactions relate to the ocular system. In a 5-year, open-label safety study with latanoprost, 33% of patients developed iris pigmentation (see 4.4). Other ocular adverse reactions are generally transient and occur when the dose is administered.</p><p>&nbsp;</p><p><u>b. Tabulated list of adverse reactions</u></p><p>Adverse reactions are classified according to their frequency, as follows: very common (&ge; 1/10), common (&ge; 1/100, &lt; 1/10), uncommon (&ge; 1/1,000, &lt; 1/100), rare (&ge; 1/10,000, &lt; 1/1,000), and very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>&nbsp;&ge; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>&lt; 1/10,000</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Herpetic keratitis*&sect;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache*, dizziness*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Iris hyperpigmentation, mild to moderate conjunctival hyperaemia, eye irritation (burning grittiness, itching, stinging and<strong> </strong>foreign body sensation), eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation and number of eyelashes)</p></td><td style="vertical-align:top"><p>Punctate keratitis, mostly without symptoms, blepharitis, eye pain, photophobia, conjunctivitis*</p></td><td style="vertical-align:top"><p>Eyelid oedema, dry eye, keratitis*, vision blurred, macular oedema including cystoid macular oedema*, uveitis*</p></td><td style="vertical-align:top"><p>Iritis*, corneal oedema*, corneal erosion, periorbital oedema, trichiasis*, distichiasis, iris cyst*&sect;, localised skin reaction on the eyelids, darkening of the palpebral skin of the eyelids, pseudopemphigoid of ocular conjunctiva<sup>*</sup>&sect;</p></td><td style="vertical-align:top"><p>Periorbital and lid changes resulting in deepening of the eyelid sulcus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angina, palpitations*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angina unstable</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthma*, dyspnoea*</p></td><td style="vertical-align:top"><p>Asthma exacerbation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea*;</p><p>vomiting*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia*, arthralgia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest pain*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*Undesirable effects identified post‑marketing</p><p>&sect;Frequency of undesirable estimated using &ldquo;The Rule of 3&rdquo;</p><p>&nbsp;</p><p>Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.</p><p>&nbsp;</p><p><u>c. Description of selected adverse reactions</u></p><p>No information is provided.</p><p>&nbsp;</p><p><u>d. Paediatric population&nbsp;</u></p><p>In 2 short-term clinical trials (&le; 12 weeks), including 93 (25 and 68) paediatric patients, the safety profile was comparable to that of adults and no new adverse events were identified. The short-term safety profiles in the different paediatric subsets were also comparable (see section 5.1). The undesirable effects seen more frequently in the paediatric population than in adults are: rhinopharyngitis and fever.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local requirements</p><p><strong>&nbsp;</strong></p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Apart from ocular irritation and conjunctival hyperaemia, no other ocular effects have been described in case of Xalatan overdose.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>In case of accidental ingestion of Xalatan, the following information may be of use:</p><p>One bottle contains 125 micrograms of latanoprost. Over 90% of the dose is metabolised after the first hepatic passage. Intravenous infusion of 3 micrograms/kg in healthy volunteers caused no symptoms, but a dose of 5.5&ndash;10 micrograms/kg caused nausea, abdominal pain, vertigo, fatigue, hot flashes and excessive perspiration. In monkeys, administration of latanoprost in intravenous infusion at doses of up to 500 micrograms/kg had no major effect on the cardiovascular system.</p><p>&nbsp;</p><p>In monkeys, intravenous administration of latanoprost was associated with transient bronchoconstriction. However, in patients with moderate bronchial asthma, administration of latanoprost in the eyes at a dose 7 times greater than the clinical dose of Xalatan did not induce bronchoconstriction.</p><p>&nbsp;</p><p>In case of overdose with Xalatan, treatment should be symptomatic.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1. </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group Ophthalmologicals; Antiglaucoma preparations and miotics, prostaglandin analogues. ATC code: S01EE01</p><p>&nbsp;</p><p>The active substance latanoprost, a prostaglandin F<sub>2</sub><sub>a</sub> analogue, is a selective prostanoid FP receptor agonist which reduces IOP by increasing the outflow of aqueous humour. In humans, IOP starts to lower about 3 to 4 hours after administration; maximum effect is reached after 8 to 12 hours. The reduction in IOP continues for at least 24 hours.</p><p>&nbsp;</p><p>Studies in animals and humans indicate that the primary mechanism of action is increased uveoscleral outflow, although a slight increase in outflow capacity (decrease in outflow resistance) has been reported in &nbsp;humans.</p><p>&nbsp;</p><p>Pivotal studies have shown that Xalatan was effective as monotherapy. In addition, clinical studies have evaluated its use in combination therapy. These are, among others, studies showing the efficacy of latanoprost in association with<strong> </strong>beta-adrenergic antagonists (timolol). Short-term studies (1 or 2 weeks) suggest that the effect of latanoprost is additive to that of adrenergic agonists (dipivalyl epinephrine), oral carbonic anhydrase inhibitors (acetazolamide) and, at least partly, to that of cholinergic agonists (pilocarpine).</p><p>&nbsp;</p><p>Clinical studies have shown that latanoprost has no significant effect on the production of aqueous humour. Latanoprost does not seem to have any effect on the blood-aqueous barrier.</p><p>&nbsp;</p><p>In monkeys and at clinical doses, latanoprost has only a negligible effect, if any, on intraocular blood circulation. However, mild to moderate conjunctival or episcleral hyperaemia may occur during local treatment.</p><p>&nbsp;</p><p>Chronic treatment using latanoprost in monkey eyes, which had undergone extracapsular lens extraction did not affect the retinal blood vessels at all in fluorescein angiography.</p><p>&nbsp;</p><p>During short-term treatment, latanoprost has not induced fluorescein leakage in the posterior segment of pseudophakic human eyes.</p><p>&nbsp;</p><p>No significant pharmacological effect on the cardiovascular or respiratory system has been observed with latanoprost at clinical doses.</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>The efficacy of Xalatan in paediatric patients &le; 18 years of age was demonstrated in a 12-week, double-blind clinical study comparing latanoprost to timolol in 107 patients diagnosed with ocular hypertension and paediatric glaucoma. Newborn infants were required to have a gestational age of at least 36 weeks. Patients were randomised with either latanoprost 50 &micro;g/ml once per day or timolol 0.5% (or optionally timolol 0.25% for subjects less than 3 years old) twice per day. The primary efficacy endpoint was the mean reduction from baseline IOP after 12 weeks of treatment. The mean IOP reduction was similar in the 2 groups treated (latanoprost and timolol). In all age groups studied (0 to &lt; 3 years, 3 to &lt; 12 years and 12 to 18 years) the mean reduction in IOP after 12 weeks of treatment in the latanoprost group was similar to that of the timolol group. However, efficacy data in the latanoprost group for the 0 to &lt; 3 years age group were based on only 13 patients and no relevant efficacy was shown in the 4 patients age 0 to &lt; 1 year old in the clinical paediatric study. No data are available for preterm infants (gestational age less than 36 weeks).</p><p>&nbsp;</p><p>Similarly, reduction of IOP among subjects in the PCG subgroup were similar between in the 2 groups treated (latanoprost and timolol). Similar results were observed in the other sub-group (Non-PCG, e.g.: juvenile open-angle glaucoma, aphakic glaucoma).</p><p>&nbsp;</p><p>The effect on IOP was seen after the first week of treatment (see table) and was maintained during the 12 weeks of the study, as in adults.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:637px"><thead><tr><td colspan="5" style="vertical-align:top"><p><strong>Table: Reduction in IOP (mmHg) after 12 weeks by active treatment group and baseline diagnosis</strong></p></td></tr><tr><td style="vertical-align:top"><p><br />&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Latanoprost</strong><br /><strong>N=53</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Timolol</strong><br /><strong>N=54</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean at inclusion (SD)</p></td><td colspan="2" style="vertical-align:top"><p>27.3 (0.75)</p></td><td colspan="2" style="vertical-align:top"><p>27.8 (0.84)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change from baseline after 12 weeks of treatment<sup>&dagger; </sup>(SD)</p></td><td colspan="2" style="vertical-align:top"><p>-7.18 (0.81)</p></td><td colspan="2" style="vertical-align:top"><p>-5.72 (0.81)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; p-value compared to timolol</p></td><td colspan="4" style="vertical-align:top"><p>0.2056</p></td></tr><tr><td style="vertical-align:top"><p><br />&nbsp;</p></td><td style="vertical-align:top"><p><strong>PCG</strong><br /><strong>N=28</strong></p></td><td style="vertical-align:top"><p><strong>Non-PCG</strong></p><p><strong>N=25</strong></p></td><td style="vertical-align:top"><p><strong>PCG</strong></p><p><strong>N=26</strong></p></td><td style="vertical-align:top"><p><strong>Non-PCG</strong><br /><strong>N=28</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean at inclusion (SD)</p></td><td style="vertical-align:top"><p>26.5 (0.72)</p></td><td style="vertical-align:top"><p>28.2 (1.37)</p></td><td style="vertical-align:top"><p>26.3 (0.95)</p></td><td style="vertical-align:top"><p>29.1 (1.33)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change from baseline after 12 weeks of treatment<sup>&dagger; </sup>(SD)</p></td><td style="vertical-align:top"><p>-5.90 (0.98)</p></td><td style="vertical-align:top"><p>-8.66 (1.25)</p></td><td style="vertical-align:top"><p>-5.34 (1.02)</p></td><td style="vertical-align:top"><p>-6.02 (1.18)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; p-value compared to timolol</p></td><td style="vertical-align:top"><p>0.6957</p></td><td style="vertical-align:top"><p>0.1317</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></thead></table><p>SD: standard deviation,</p><p><sup>&dagger;</sup>Adjusted mean based on analysis of covariance (ANCOVA) model</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Latanoprost (molecular weight 432.58) is an isopropyl ester prodrug which per se is inactive but which, after hydrolysis to acid of latanoprost, becomes biologically active.</p><p>&nbsp;</p><p>The prodrug is well-absorbed through the cornea and all of the medicinal product that penetrates the aqueous humour is hydrolysed during passage through the cornea.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Studies in human beings indicate that the peak concentration in the aqueous humour is reached about 2 hours after topical administration. After topical application in monkeys, latanoprost is primarily distributed in the anterior segment, the conjunctivae and the eyelids. Only minute quantities of the medicine reach the posterior segment.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>There is practically no metabolism of the acid of latanoprost in the eye. Metabolism is mainly hepatic. The plasma half-life in humans is about 17 minutes. In animal studies, the primary metabolites, the 1,2-dinor and 1,2,3,4-tetranor metabolites, had only a weak biological activity, if any, and were primarily excreted in the urine.</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>An open-label pharmacokinetic study of plasma concentrations of latanoprost acid was undertaken in 22 adults and 25 paediatric patients (from birth to &lt; 18 years of age) with ocular hypertension and glaucoma. All age groups were treated with latanoprost 50 &micro;g/mL, one drop per day in each eye for a minimum of 2 weeks. Systemic exposure to latanoprost acid was approximately 2-fold higher in children ages 3 to &lt; 12 and 6-fold higher in children less than 3 years old compared to adults, but a wide safety margin for systemic undesirable effects was maintained (see section 4.9). Mean time to reach peak plasma concentration was 5 minutes after dose administration across all age groups. The mean plasma elimination half-life was short (&lt; 20 minutes) and similar for paediatric and adult patients, resulting in no accumulation of latanoprost acid in the systemic circulation at steady state.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The ocular and systemic toxicity of latanoprost has been studied in various animal species. Generally, latanoprost is well-tolerated with a high safety margin, systemic toxicity being at least 1,000 times greater than the clinical ocular dose. Intravenous administration of high doses of latanoprost, approximately 100 times the clinical dose/kg of body weight, in non-anaesthetised monkeys, caused an increase in respiratory rate. This probably reflects a short-term bronchoconstriction.&nbsp; No sensitising properties of latanoprost have been observed in animal studies.</p><p>&nbsp;</p><p>No toxic effects have been observed in rabbits and monkeys receiving doses of a maximum of 100 micrograms/eye/day (the clinical dose is around 1.5 micrograms/eye/day). In monkeys, however, latanoprost has shown that it induces an increase in iris pigmentation.</p><p>&nbsp;</p><p>The mechanism of increased pigmentation seems to be a stimulation of the production of melanin in the melanocytes of the iris, without proliferative change. This change in colour of the iris can be permanent.</p><p>&nbsp;</p><p>In studies on chronic ocular toxicity, administration of latanoprost at a dose of 6 micrograms/eye/day has also induced increased palpebral fissure. This effect is reversible and appears at doses higher than the clinical dose. This effect has not been observed in humans.</p><p>Reverse mutation tests on bacteria, genetic mutation tests on mouse lymphoma, and the mouse micronucleus test have all given negative results for latanoprost. Chromosomal aberrations have been observed in vitro on human lymphocytes. Similar effects have been observed with prostaglandin F<sub>2</sub><sub>a</sub>, a natural prostaglandin, which suggests that this is a class effect.</p><p>&nbsp;</p><p>Other mutagenicity studies on in vitro/in vivo unscheduled DNA synthesis in rats have been negative and indicate that latanoprost has no mutagenic toxicity. Carcinogenicity studies conducted in mice and rats were negative.</p><p>&nbsp;</p><p>In animal studies, no effect of latanoprost has been demonstrated on male or female fertility. In an embryotoxicity study conducted in rats, no embryotoxicity was observed at intravenous doses of 5, 50 and 250 micrograms/kg/day of latanoprost. However, in rabbits, latanoprost induced embryolethal effects at doses of 5 micrograms/kg/day or greater.</p><p>&nbsp;</p><p>The dose of 5 micrograms/kg/day (about 100 times the clinical dose) induced significant embryo-foetal toxicity, characterised by increased incidence of late resorptions and abortions, as well as a reduction in foetal birth weight.</p><p>&nbsp;</p><p>There is no evidence of teratogenic potential.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Sodium chloride</p><p>Benzalkonium chloride</p><p>Sodium dihydrogen phosphate monohydrate</p><p>Disodium phosphate anhydrous</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> studies have shown that there is precipitation when eye drops containing thiomersal are mixed with Xalatan. If such medicinal products are used, the eye drops should be administered at an interval of at least 5 minutes.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Xalatan after the expiry date which is stated on the carton label after EXP:. The expiry date refers to the last day of that month

Before first opening: 3 years

After first opening of container: 4 weeks


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>After first opening the bottle: Do not store above 25&deg;C and use within 4 weeks (see section 6.3).</p><p>&nbsp;</p><p>Keep the bottle in the outer carton in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Dropper container (5&nbsp;mL) of polyethylene with a screw cap and tamper evident overcap of polyethylene.</p><p>Each dropper bottle contains 2.5 mL Eye drops corresponding to approximately 80 drops of solution.</p><p>&nbsp;</p><p>Pack sizes: 1 x 2.5 mL, 3 x 2.5 mL, 6 x 2.5 mL.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Upjohn SRL, Boulevard De la Plaine 17, 1050 Bruxelles, Belgium.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>